Showing 2231-2240 of 6036 results for "".
- Visus Therapeutics Announces FDA Acceptance of IND to Proceed With Clinical Development of Presbyopia-Correcting Eye Drophttps://modernod.com/news/visus-therapeutics-announces-fda-acceptance-of-ind-for-presbyopia-correcting-eye-drop/2478973/Visus Therapeutics announced that the FDA has accepted the company’s investigational new drug application (IND) to proceed with the clinical development program for Brimochol, the company’s lead investigational asset. Under this IND, Visus will initiate its planned phase 2 clinical trial in the U
- Johnson & Johnson Vision Introduces Acuvue Oasys Multifocal with Pupil Optimized Designhttps://modernod.com/news/johnson-johnson-vision-introduces-acuvue-oasys-multifocal-with-pupil-optimized-design/2478970/Johnson & Johnson Vision has introduced a new eye care option for patients with presbyopia: Acuvue Oasys Multifocal Contact Lenses with Pupil Optimized Design. The new lens is now available in the United States and Canada.
- NIH-Led Team Sets New Bar in Retinal Imaginghttps://modernod.com/news/nih-led-team-sets-new-bar-in-retinal-imaging/2478963/A team led by scientists at the National Eye Institute (NEI) has noninvasively visualized the light-sensing cells in the back of the eye, known as photoreceptors, in greater detail than ever before. Published in Optica, the researchers report how they improved imaging resolution by a thi
- ASCRS Introduces Richard L. Lindstrom Lecture for 2021 Annual Meetinghttps://modernod.com/news/ascrs-introduces-richard-l-lindstrom-lecture-for-2021-annual-meeting/2478960/The American Society of Cataract and Refractive Surgery (ASCRS) has announced the inaugural Richard L. Lindstrom Lecture and Medal, which will be delivered along with other distinguished lectures at the 2021 ASCRS Annual Meeting in Las Vegas, Nevada. The Richard L. Lindstrom Lecture and Me
- Visus Therapeutics Announces $36 Million Series A Financing to Advance Development of Novel Presbyopia-Correcting Eye Drophttps://modernod.com/news/visus-therapeutics-announces-36-million-series-a-financing-to-advance-development-of-novel-presbyopia-correcting-eye-drop/2478952/Visus Therapeutics announced the close of a $36 million Series A Preferred Stock financing to advance the clinical development program for the company’s lead asset, Brimochol, an investigational drug designed to be a
- Researchers Develop New Noninvasive Technique to Image Human Eyehttps://modernod.com/news/researchers-develop-new-noninvasive-technique-to-image-human-eye/2478947/Researchers have developed a noninvasive technique that can capture images of rod and cone photoreceptors with unprecedented detail. The advance could lead to new treatments and earlier detection for retinal diseases such as macular degeneration, according to a National Eye Institute news release
- Retinal Therapeutics Development Company Oxular Completes $37 Million (£27 million) Financinghttps://modernod.com/news/retinal-therapeutics-development-company-oxular-completes-37-million-27-million-financing/2478922/Oxular announced that it has completed a $37 million (£27 million) to fund planned further clinical development of its lead asset, OXU-001, for the treatment of diabetic macular edema (DME), as well as accelerating development of its early-product pipeline. The financing was led by Forbion
- Researchers Use Patients’ Cells to Test Gene Therapy for a Form of Leber Congenital Amauroshttps://modernod.com/news/researchers-use-patients-cells-to-test-gene-therapy-for-a-form-of-leber-congenital-amauros/2478810/Scientists at the National Eye Institute (NEI) have developed a promising gene therapy strategy for a rare disease that causes severe vision loss in childhood. A form of Leber congenital amaurosis, the disease is caused by autosomal-dominant mutations in the CRX gene, which are ch
- Zenni Releases New Anti-Fog Glasses Lenses to Address Mask-Related Fogginghttps://modernod.com/news/zenni-releases-new-anti-fog-glasses-lenses-to-address-mask-related-fogging/2478797/Zenni announced a 2-in-1 anti-fog + anti-reflective lens solution to solve a pain point for glasses wearers during the pandemic. Developed in 2020 as a response to the pervasive consumer issue of glasses fogging up while wearing face coverings, these new anti-fog coated lenses are the only low pr
- Alcon Launches Precision1 for Astigmatism Contact Lenses in the UShttps://modernod.com/news/alcon-launches-precision1-for-astigmatism-contact-lenses-in-the-us/2478780/Alcon announced the US launch of Precision1 for Astigmatism, a daily disposable, silicone hydrogel (SiHy) contact lens designed for astigmatic patients. “Precision1, with its cutting-edge Smartsurface technology, has become the fastest-growing daily disposable contact lens brand in the U.S